Title: Meta-analysis of effectiveness of traditional Chinese medicine as adjuvant therapy of Levodopa medicine for Parkinson disease
Abstract:Objective To assess the effectiveness of traditional Chinese medicine(TCM) as adjuvant therapy of Levodopa medicine in improving symptom of Parkinson disease. Methods Clinical randomized controlled tr...Objective To assess the effectiveness of traditional Chinese medicine(TCM) as adjuvant therapy of Levodopa medicine in improving symptom of Parkinson disease. Methods Clinical randomized controlled trials on TCM as adjuvant therapy of Levodopa medicine in improving symptom of Parkinson disease were searched from databases of CNKI, VIP, CBM, Wanfang, Pub Med, Springer-link, EBSCO, Elsevier-SDOL from October 1994 to October 2014.Outcome measure was unified Parkinson disease rating scale(UPDRS). According to the inclusion criteria and exclusion criteria literatures were selected and Revman 5.3 was utilized for a Meta-analysis on data collected from literatures. Results 19 randomized controlled trials were concluded. A total of 1352 cases were included, control group(Levodopa medicine or plus placebo) were 671 cases and experimental group(TCM and Levodopa medicine) were 681 cases. Outcome of Meta-analysis showed that the scores of UPDRS in experimental group were lower than control group and the difference was statistically significant. UPDRSⅠ [WMD =-0.76, 95%CI(-1.30,-0.23), P = 0.005], UPDRSⅡ[WMD =-3.07, 95%CI(-4.18,-1.97), P 0.000 01], UPDRSⅢ[WMD =-4.09, 95%CI(-5.05,-3.12), P 0.000 01],UPDRSⅡ and UPFRSⅢ [WMD =-7.01, 95%CI(-11.61,-2.41), P = 0.003], UPDRSⅣ [SMD =-0.63, 95%CI(-1.00,-0.26), P = 0.0009], the total score of UPDRS [SMD =-7.32, 95%CI(-8.50,-6.13), P 0.000 01]. Conclusion The effectiveness of TCM as adjuvant therapy of Levodopa medicine is better than only using Levodopa medicine in improving symptom of Parkinson disease.Read More
Publication Year: 2015
Publication Date: 2015-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot